[CAS NO. 2446816-88-0] Inaxaplin
PRODUCTS SPECIFICATIONS [2446816-88-0]
DESCRIPTION [2446816-88-0]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 417.38 |
| Molecular Formula | C21H18F3N3O3 |
| SMILES | O[C@H](CNC1=O)[C@@H]1NC(CCC(C2=CC(F)=C3)=C(C4=CC=C(C=C4)F)NC2=C3F)=O |
Summary
Inaxaplin (VX-147) is an orally active apolipoprotein L1 ( APOL1 ) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease [1] .
IC50 & Target
APOL1 [1]
In Vitro
Inaxaplin is an apolipoprotein L1 function inhibitor [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04340362 | Vertex Pharmaceuticals Incorporated |
Glomerulosclerosis, Focal Segmental
|
June 8, 2020 | Phase 2 |
| NCT05312879 | Vertex Pharmaceuticals Incorporated |
Proteinuric Kidney Disease
|
March 30, 2022 | Phase 2|Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 119.79 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3959 mL | 11.9795 mL | 23.9590 mL |
| 5 mM | 0.4792 mL | 2.3959 mL | 4.7918 mL |
| 10 mM | 0.2396 mL | 1.1979 mL | 2.3959 mL |
References